Sanofi's stock has dropped due to a trial loss for a breast cancer medication

Sanofi's stock has dropped due to a trial loss for a breast cancer medication ...

In a clinical trial, Sanofi's stock has dropped 5.3 percent as a pharmacist candidate fought a common type of breast cancer that grows in response to oestrogen failed to slow the progression of the disease.

The results from the Phase II AMEE ...

Read more in the source

You may also like: